Explore Our Network

Aceso Plasma develops investigational cold plasma medical devices focused on wound care, dermatology, and defense decontamination applications. Their flagship handheld device generates non-thermal, localized plasma from ambient air, supporting accelerated wound healing and reducing microbial and biofilm burden without increasing antimicrobial resistance. The technology has been validated in pre-clinical and investigational studies at multiple independent research institutes, including military and academic partners, and is currently advancing towards FDA clearance.

Akthelia Pharmaceuticals is a pioneering biopharmaceutical company focused on developing therapeutics that enhance the body's innate defense mechanisms to combat debilitating diseases. The company targets mucosal barrier injury and epithelial integrity through a novel immunotherapeutic strategy. Its mission is to revolutionize treatment for diseases such as cancer, infection, and autoimmune disorders by leveraging the body's own microbial defense mechanisms.

Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

Auxilium Health, Inc. is dedicated to providing innovative solutions for wound healing, focusing on delivering smarter and more effective care for patients. Their mission is to enhance the healing process, one patient at a time.

AvantGuard has developed a novel broad-spectrum, bio-compatible antiseptic that is proven in in vitro, ex vivo, and in vivo testing to be safe and more effective than topical antibiotics, while also effective as a liquid sterilant or disinfectant. Our compound, Avantamine, can be packaged as a heat-tolerant, long-shelf-life powder in a metal foil packet that dissolves rapidly in potable water to make either a solution or hydrogel. At a high concentration, Avantamine's non-hazardous, non-corrosive solution will sterilize medical equipment in 10 minutes and is safe enough for instruments to be removed and used without rinsing. Diluted by half, Avant24 at 0.6% concentration is (1) an antiseptic for washing wounds or treating cutaneous bacterial and fungal infections, (2) a high-level disinfectant for a variety of medical devices without corroding metals or degrading plastics, and (3) a disinfectant for surfaces in the surgical suite. At 6X further dilution, Avant24 can treat trench mouth. At another 3X dilution, Avant24 can be added to water to make it drinkable. There are an enormous number of potential uses and the only difference between them is the amount of diluent, in this case water, used to prepare the solution. Our military focus areas are (1) low resource sterilization of medial devices, (2) fungal treatment for burn wounds, and (3) a prophylactic for infection control in a self-administered Role 1 environment with the powder applied directly to a wound. Our commercial focus area is Candida auris decolonization which is not currently possible with any other antiseptic. We have definitive animal testing to show efficacy and superiority to chlorhexidine and are moving toward the clinic.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

Bench in a Box Technologies develops point-of-care diagnostic platforms tailored for field and low-resource environments. The company's core technology, Protein Signal Amplification (PSA), allows rapid, electricity-free molecular detection at room temperature, delivering results in five minutes or less, without the need for refrigeration or specialized laboratory infrastructure. Drawing on extensive expertise in molecular diagnostics, drug development, and logistics, the company aims to make high-quality diagnostics broadly accessible.

Biophoundry specializes in advancing scalable engineered phage-based solutions for therapeutics, diagnostics, and bio-molecular engineering. It is shifting the paradigm from phage discovery to phage design. Its team leverages expertise in synthetic biology, machine learning, and data science to accelerate the development of precision antibiotics and address critical healthcare challenges such as antimicrobial resistance.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Case Western Reserve University is dedicated to solving the biggest issues of today and tomorrow through innovative research and education. With a commitment to experiential learning, the university offers a wide range of programs and opportunities for students to engage in research, internships, and community service, all within a vibrant campus located in Cleveland, Ohio.

Clear Choice Therapeutics specializes in advanced wound care, with a focus on negative pressure wound therapy (NPWT) systems designed by orthopedic surgeons for both civilian and military applications. The company has developed FDA-cleared dressing kits and contact layers using proprietary transparent thermoplastic elastomer materials. Its NPWT solutions emphasize efficient fluid evacuation, enhanced wound visualization, reduced pain during dressing changes, and decreased infection risk—offering improvements over traditional foam-based wound therapies. The PREVENT allows for Low Pressure Wound Therapy (-50mmHg) which avoids high suction levels. Traditional foam NPWT can result in high downward forces on wounds resulting in decreased tissue perfusion and delayed healing.

Clyra Medical Technologies is a healthcare company dedicated to improving lives by developing and commercializing innovative products for wound and skin infection treatment. As a subsidiary of BioLargo, Inc., Clyra focuses on creating safe, effective, and cost-efficient solutions that reduce the need for antibiotics and promote wound healing. Their technology, based on a copper-iodine complex, offers a broad-spectrum antimicrobial effect without known microbial resistance, making it suitable for various healthcare settings.

Commense Bio is a biopharmaceutical company focusing on developing genetically engineered bacterial therapeutics for invasive infections. With a proprietary technology platform, the company is advancing live biotherapeutic products (LBPs) addressing various infectious diseases including MRSA, recurrent UTIs, cystic fibrosis-associated infections, and more. Their innovations center around gene-edited bacteria and microbiome substitution—with a single, prescription-only application administered dermally or nasally—as a novel, non-antibiotic approach against antimicrobial resistance. The team includes experience in drug development, commercialization, and scientific research.

Critical Innovations LLC is a medical research and development company focused on creating cutting-edge solutions to health threats across pre-hospital, hospital, and military environments. The company focuses on task-shifting evidence-based interventions to earlier echelons of care and more general specialty levels, to simplify management and allow for rapid provision in emergency and combat environments. The company is dedicated to developing innovative medical devices and technologies that enhance emergency care and trauma management, particularly in military settings.

Ethos Solutions specializes in rapid problem solving in dynamic environments through the Ethos IDEALs (Identification, Define, Engagement, Alignment, and Leveraging). Ethos leverages module working groups (or cells) consisting of Subject Matter Expert (SMEs) clinicians, training cadre, warriors, academics, and researchers able to rapidly identify and solve problem sets that require a grounded approach forged in austere and dynamic environments.

FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.

Flen Health develops, manufactures, and distributes advanced biotechnological solutions for wound and skin healing. Its offerings include topical dressings, gels, cleansers, and educational resources for both clinical professionals and patients. Operating globally in over 40 countries, Flen Health emphasizes research-driven product development, clinical education, and international collaboration to promote inclusive and effective wound care.

The GE HealthCare Technology & Innovation Center (HTIC) traces its roots to America's first industrial research facility, established by General Electric in 1900. Today, HTIC scientists tackle healthcare challenges through federal funding, academic collaboration, and private sector development. HTIC enhances GE HealthCare competitiveness through development of innovative technologies that enable creation of differentiated and disruptive products. HTIC engages in exploratory research in collaboration with clinicians and academia, guided by societal needs and governmental priorities to discover new markets. With operations in Niskayuna, NY, USA and Bangalore, India, HTIC translates federal research investments into clinical applications.